Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support (RISE)
24 augustus 2026 bijgewerkt door: Stephan Baldus, University Hospital of Cologne
Rapid Impella Support and Escalation Trial
The aim of this trial is to evaluate whether a structured and time-optimized escalation strategy from a transfemoral microaxial flow-pump (Impella CP™) to the Impella 5.5™ microaxial flow-pump is associated with improved clinical outcomes and fewer adverse events in patients with cardiogenic shock due to acute myocardial infarction
Studie Overzicht
Toestand
Werving
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
By examining best-practice MCS management and the role of early escalation to Impella 5.5™ in clinical routine care for high-risk patients with deteriorating shock, the study seeks to investigate current treatment strategies that ensure the most appropriate device selection and support intensity at the earliest clinically meaningful time point.
This observational approach aims to advance the optimal management of ACS-CS while addressing the complications reported in the DanGer Shock trial.
Studietype
Observationeel
Inschrijving (Geschat)
115
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Sebastian Heyne, Dr. med.
- Telefoonnummer: +4915125364083
- E-mail: sebastian.heyne@uk-koeln.de
Studie Locaties
-
-
-
Cologne, Duitsland, 50937
- Werving
- University Hospital Cologne
-
Contact:
- Sebastian Heyne, Dr. med.
- Telefoonnummer: +49 221 478 84452
- E-mail: sebastian.heyne@uk-koeln.de
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Duitsland, 40225
- Werving
- University Hospital Düsseldorf
-
Contact:
- Malte Kelm, Prof.
- Telefoonnummer: +49 211 8118801
- E-mail: kardiologie@med.uni-duesseldorf.de
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Duitsland, 24105
- Werving
- University Hospital Schleswig-Holstein, Campus Kiel
-
Contact:
- Bernd Panholzer, Dr.med.
- Telefoonnummer: +49 431 50028193
- E-mail: Bernd.Panholzer@uksh.de
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Nee
Bemonsteringsmethode
Niet-waarschijnlijkheidssteekproef
Studie Bevolking
Patients with ACS-CS (STEMI or NSTEMI) who undergo Impella CP™-supported revascularisation of the culprit lesion and are considered for escalation to Impella 5.5 at the discretion of the treating investigator will be assessed for eligibility to participate in this observational study.
Beschrijving
Inclusion Criteria:
- Age ≥18 years and ≤77 years
- Patients with ACS-CS (STEMI and NSTEMI with a culprit lesion that received revascularisation) and Impella CP™ support during initial revascularisation
The following additional parameters must be met at the time of initial revascularisation procedure:
- Hypotension or need for inotropes AND
- Lactate > 2.5 mM AND
- Left ventricular ejection fraction (EF) < 45%
Need for escalation to Impella 5.5 at the discretion of the treating physician and the following criteria are fulfilled:
- Decision for Impella 5.5 escalation within 6 ± 1 hours after completion of initial revascularisation procedure
- Escalation to Impella 5.5procedure is initiated within 24 hours after completion of the initial revascularisation procedure
- Need for inotropes and/or vasopressors with VIS > 5 but ≤ 50 at Impella CP™ support at level P7 or above at 6+1 hours after completion of initial revascularisation procedure
- Prospective Informed Consent obtained from the patient or deferred consent according to "Cologne Model" applied.
Exclusion Criteria:
- Implanted VA-ECMOwithin 6 ± 1 hours after initial revascularisation Note: If VA-ECMO support is needed between 6 ± 1 hours after initial revascularisation and escalation to Impella 5.5, patients will be included forlimited data collection per Table 2 only. In this case the same Informed Consent Process as for regular trial participants applies.
- Elevated risk of hypoxic brain injury indicated by MIRACLE2 score >3 (Aldous et al., 2023)
- Platelet count <75,000 cells/mm3, bleeding diathesis or active bleeding, coagulopathy or unwillingness to receive blood transfusions
- Active bleeding (e.g. access site bleeding or GI bleeding, etc.) with need for transfusion within 6 ± 1 hours after initial revascularisation
- Any contraindication listed in the Impella 5.5 IFU if known to be present
- Chronic haemodialysis and/or chronic kidney disease stage G5 according to KDIGO
- Pregnancy or lactation, if known
- Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not reached its primary endpoint, if known
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Device Group
Rapid escalation to Impella 5.5
|
Rapid escalation from Impella CP to Impella 5.5 within 24 hours post revascularization
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Vasoactive Hemodynamic Score (VHS) < 5
Tijdsspanne: 48 hours post revascularization
|
Vasoactive Hemodynamic Score = Hemodynamic Score (HS) x Vasoactive-Inotropic Score (VIS) Higher VHS indicates more severe hemodynamic compromise relative to degree of pharmacological circulatory support. Range: Minimum 1, Maximum 110 Hemodynamic Score: HS = Points are allocated for measured heart rate, mean arterial blood pressure and arterial lactate (minimum 1, maximum 11) Vasoactive-Inotropic Score: Points are allocated for every 10 increment according to the following formula: Dopamine dose (μg/kg/min) + Dobutamine dose (μg/kg/min) + 100 x Epinephrine dose (μg/kg/min) + 10 x Milrinone (μg/kg/min) + 100 x Norepinephrine dose (μg/kg/min) + 50 x Levosimendan dose (μg/kg/min) |
48 hours post revascularization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
All-cause mortality
Tijdsspanne: In-hospital or 30 days post revascularization (whatever comes first)
|
In-hospital or 30 days post revascularization (whatever comes first)
|
|
|
All-cause mortality
Tijdsspanne: 180 days post revascularization
|
180 days post revascularization
|
|
|
Cardiac output
Tijdsspanne: At time of enrolment, 48 hours as well as 72 hours post revascularization.
|
measured by pulmonary artery catheter (PAC) [l/min]
|
At time of enrolment, 48 hours as well as 72 hours post revascularization.
|
|
Vasoactive-Inotropic Score (VIS)
Tijdsspanne: At time of enrolment, 48 hours as well as 72 hours post revascularization.
|
Vasoactive-Inotropic Score (VIS): A composite measure of vasoactive and inotropic medication support. Scores range from 0 to no fixed maximum, with higher scores indicating greater vasoactive/inotropic support requirements and therefore a worse clinical status and prognosis. VIS=dopamine + dobutamine + 100×epinephrine + 10×milrinone + 10,000×vasopressin + 100×norepinephrine (all doses in μg/kg/min except vasopressin in U/kg/min) |
At time of enrolment, 48 hours as well as 72 hours post revascularization.
|
|
Lactate
Tijdsspanne: At time of enrolment, 48 hours as well as 72 hours post revascularisation
|
Arterial lactate measured by blood gas analysis [mmol/l]
|
At time of enrolment, 48 hours as well as 72 hours post revascularisation
|
|
Perfusion
Tijdsspanne: At time of enrolment and 48 hours post revascularization.
|
Enhanced perfusion of the limb used for Impella CP™ access by comparing NIRS measurements [%]
|
At time of enrolment and 48 hours post revascularization.
|
|
Major Bleeding
Tijdsspanne: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) until the first documented bleeding event.
|
Either according to BARC classification (BARC ≥ IIIa) or GUSTO classification (at least moderate bleeding)
|
During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) until the first documented bleeding event.
|
|
Ischemia of the extremities
Tijdsspanne: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timepoint of intervention/surgery assessed up to 30 days.
|
Peripheral vascular ischemia (femoral and axillary) with indication to percutaneous intervention or surgical repair
|
During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timepoint of intervention/surgery assessed up to 30 days.
|
|
Haemolysis
Tijdsspanne: At time of enrolment, 48 hours as well as 72 hours post revascularization.
|
Prevalence of clinically relevant haemolysis according to SHARC definitions
|
At time of enrolment, 48 hours as well as 72 hours post revascularization.
|
|
Cerebral events
Tijdsspanne: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) assessed up to 30 days.
|
Cerebral ischemia or cerebral bleeding assessed via standard-of-care neurological assessment and/or imaging
|
During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) assessed up to 30 days.
|
|
Acute kidney injury (AKI)
Tijdsspanne: Every event during the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first), assessed at the timepoint of occurence up to 30 days.
|
Acute kidney injury (AKIN level 2 or greater) and/or need for renal replacement therapy (RRT)
|
Every event during the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first), assessed at the timepoint of occurence up to 30 days.
|
|
Sepsis with positive blood culture
Tijdsspanne: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timpoint of first positive blood culture up to 30 days.
|
During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death of any cause (whichever comes first) at the timpoint of first positive blood culture up to 30 days.
|
|
|
Access site infection
Tijdsspanne: During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death (whichever comes first), at the timepoint of surgical intervention up to 30 days.
|
Access site infection with the need to surgical intervention
|
During the index hospitalization, specifically from timepoint of initial revascularisation until discharge from the index hospitalization or death (whichever comes first), at the timepoint of surgical intervention up to 30 days.
|
|
Time to extubation
Tijdsspanne: At 30 days post revascularization
|
Time to extubation in hours
|
At 30 days post revascularization
|
|
Time to ambulation
Tijdsspanne: At 30 days post revascularization
|
Time to ambulation in hours
|
At 30 days post revascularization
|
|
Cumulative incidence of escalation to VA-ECMO, LVAD or heart transplant
Tijdsspanne: At 30 days and 180 days post revascularization
|
Cumulative incidence of escalation to VA-ECMO, LVAD or heart transplant
|
At 30 days and 180 days post revascularization
|
|
Major adverse kidney events (MAKE)
Tijdsspanne: At 30 days and 180 days post revascularization
|
Death (from any cause) or new requirement for renal replacement therapy (RRT) (e.g., dialysis) or persistent renal dysfunction (PRD) (defined as a worsening of kidney function denoted by ≥ 25% decline in the estimated glomerular filtration rate (eGFR) from baseline)
|
At 30 days and 180 days post revascularization
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
23 april 2026
Primaire voltooiing (Geschat)
1 oktober 2028
Studie voltooiing (Geschat)
1 oktober 2028
Studieregistratiedata
Eerst ingediend
21 april 2026
Eerst ingediend dat voldeed aan de QC-criteria
15 juni 2026
Eerst geplaatst (Werkelijk)
17 juni 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
27 augustus 2026
Laatste update ingediend die voldeed aan QC-criteria
24 augustus 2026
Laatst geverifieerd
1 augustus 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 25-1387
- HORIZON-JU-IHI-2025-09 (Ander subsidie-/financieringsnummer: IHI Joint Undertaking)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
Due to data protection regulations and study contracts
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Ja
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .